We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bleeding Time Study With AZD6482, Clopidogrel and ASA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00853450
Recruitment Status : Completed
First Posted : March 2, 2009
Last Update Posted : August 19, 2009
Information provided by:

February 27, 2009
March 2, 2009
August 19, 2009
February 2009
Not Provided
Capillary Bleeding Time (CBT) [ Time Frame: Prior to first dose in each treatment period, on study day 6 and 7 in treatment period A and on study day 7 in treatment period B ]
Same as current
Complete list of historical versions of study NCT00853450 on ClinicalTrials.gov Archive Site
  • Effect on bleeding [ Time Frame: Prior to first dose in each treatment period, twice on study day 6 and three times on study day 7 in treatment period A and twice on study day 7 in treatment period B ]
  • Pharmacokinetics [ Time Frame: Prior to AZD6482 infusion and repeatedly during 6 hours after end of infusion ]
  • Safety variables (adverse events, blood pressure, pulse, ECG, safety lab) [ Time Frame: Repeatedly during the study ]
Same as current
Not Provided
Not Provided
Bleeding Time Study With AZD6482, Clopidogrel and ASA
A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Antiplatelet Effect
  • Drug: AZD6482
    Single intravenous infusion during a maximum of 5 hours
  • Drug: Clopidogrel
    Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
    Other Name: Plavix®
  • Drug: ASA
    75 mg orally once daily during 7 days in each treatment arm
    Other Name: Trombyl®
  • Experimental: 1
    AZD6482 on top of ASA
    • Drug: AZD6482
    • Drug: ASA
  • Active Comparator: 2
    Clopidogrel on top of ASA
    • Drug: Clopidogrel
    • Drug: ASA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2009
Not Provided

Inclusion Criteria:

  • BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive
  • Provision of written informed consent

Exclusion Criteria:

  • Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.
  • Acute illness, surgical procedure or trauma from 2 weeks before pre-entry visit until the first baseline visit or clinically significant abnormalities in clinical chemistry, haematology, urinalysis or supine BP or pulse
  • Known impaired glucose tolerance, known galactose intolerance, total lactase deficiency or glucose-galactose malabsorption or known or suspected Gilbert's syndrome
Sexes Eligible for Study: Male
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
EudraCT no. 2008-007030-21
Not Provided
Not Provided
Peter Held, Medical Science Director, Early Thrombosis & Haemostasis, AstraZeneca
Not Provided
Study Director: Peter Held AstraZeneca Mölndal
Principal Investigator: Bo Fransson, MD AstraZeneca Clinical Pharmacology Unit, Lund
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP